Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Return on Capital Employed (2022 - 2026)

Orchestra BioMed Holdings has reported Return on Capital Employed over the past 5 years, most recently at 58.43% for Q1 2026.

  • Quarterly Return on Capital Employed rose 7356.0% to 58.43% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 58.43% through Mar 2026, up 7356.0% year-over-year, with the annual reading at 65.76% for FY2025, 2678.0% up from the prior year.
  • Return on Capital Employed was 58.43% for Q1 2026 at Orchestra BioMed Holdings, down from 55.65% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 37.24% in Q2 2023 and troughed at 210.37% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 63.85% (2026), against an average of 85.84%.
  • Year-over-year, Return on Capital Employed crashed -11785bps in 2025 and then soared 7356bps in 2026.
  • A 5-year view of Return on Capital Employed shows it stood at 51.39% in 2022, then fell by -6bps to 54.46% in 2023, then tumbled by -98bps to 108.0% in 2024, then soared by 48bps to 55.65% in 2025, then decreased by -5bps to 58.43% in 2026.
  • Per Business Quant, the three most recent readings for OBIO's Return on Capital Employed are 58.43% (Q1 2026), 55.65% (Q4 2025), and 141.53% (Q3 2025).